Orion Biotech Opportunities registered with the SEC to offer 20 million units at $10 each to raise $200 million for the acquisition of a company in the life sciences and biotechnology sectors.
The SPAC is led by CEO and Director James Huang, a founding managing partner of VC firm Panacea Venture. Huang is also a managing partner of Kleiner Perkins Caufield & Byers China.
The SPAC intends to list on the Nasdaq under ORIAU. Read more.
